<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Microbes Infect</journal-id><journal-title-group><journal-title>Emerging Microbes &#x00026; Infections</journal-title></journal-title-group><issn pub-type="epub">2222-1751</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39585340</article-id><article-id pub-id-type="pmc">PMC12093414</article-id>
<article-id pub-id-type="publisher-id">2434587</article-id><article-id pub-id-type="doi">10.1080/22221751.2024.2434587</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="heading"><subject>Drug Resistance and Novel Antimicrobial Agents</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Isoniazid potentiates tigecycline to kill methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><alt-title alt-title-type="right-running-head">EMERGING MICROBES &#x00026; INFECTIONS</alt-title><alt-title alt-title-type="left-running-head">X.-W. CHEN ET AL.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xuan-wei</given-names></name><xref rid="AF1" ref-type="aff">a</xref><xref rid="AF2" ref-type="aff">b</xref><xref rid="an1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hao-qing</given-names></name><xref rid="AF3" ref-type="aff">c</xref><xref rid="an1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jia-han</given-names></name><xref rid="AF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhi-han</given-names></name><xref rid="AF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yu-Qing</given-names></name><xref rid="AF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Si-qi</given-names></name><xref rid="AF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Bo</given-names></name><xref rid="AF1" ref-type="aff">a</xref><xref rid="AF2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="AF1"><label>a</label>State Key Laboratory of Bio-Control, Guangdong Key Laboratory of Pharmaceutical Functional Genes, School of Life Sciences, Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai), <institution>Sun Yat-sen University</institution>, <city>Guangzhou</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF2"><label>b</label>Laboratory for Marine Biology and Biotechnology, <institution>Qingdao Marine Science and Technology Center</institution>, <city>Qingdao</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF3"><label>c</label><institution>Guangzhou Medical University</institution>, <city>Guangzhou</city>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Bo Peng <email xlink:href="pengb26@mail.sysu.edu.cn">pengb26@mail.sysu.edu.cn</email> State Key Laboratory of Bio-Control, Guangdong Key State Key Laboratory of Bio-Control, Guangdong Key Laboratory of Pharmaceutical Functional Genes, School of Life Sciences, Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai), <institution>Sun Yat-sen University</institution>, <city>Guangzhou</city>
<postal-code>510275</postal-code>, <country>People&#x02019;s Republic of China</country></corresp><fn id="an1"><label>*</label><p>These authors contribute equally.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>11</month><year>2024</year></pub-date><volume>14</volume><issue>1</issue><elocation-id seq="8">2434587</elocation-id><pub-history><event event-type="received"><date><day>25</day><month>7</month><year>2024</year></date></event><event event-type="revised"><date><day>19</day><month>11</month><year>2024</year></date></event><event event-type="accepted"><date><day>21</day><month>11</month><year>2024</year></date></event><event event-type="tagger"><event-desc>Nova techset</event-desc><date><day>27</day><month>11</month><year>2024</year></date></event><event event-type="build-issue-online"><event-desc>Converted to JATS 1.2 by Nova Techset</event-desc><date><day>27</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TEMI_14_2434587.pdf"/><abstract><title>ABSTRACT</title><p>Therapeutic option for treating methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) infection is urgently required since its resistance to a broad spectrum of currently available antibiotics. Here, we report that isoniazid is able to potentiate the killing efficacy of tigecycline to MRSA. The combination of isoniazid and tigecycline reduces the minimal inhibitory concentration of clinic MRSA strains to tigecycline. The killing activity of tigecycline is further confirmed by killing experiments and murine infection model. We further demonstrate the mechanism that isoniazid increases intracellular accumulation of tigecycline by promoting the influx but limiting the efflux of tigecycline through proton motive force. We also show that isoniazid and tigecycline synergize to increase the abundance of isoniazid-NAD adduct, which in turn damage cell membrane, possibly contributing to the disruption of PMF. Whereas phosphatidylethanolamine and cardiolipin are able to abrogate the synergistic effect of isoniazid plus tigecycline. Thus our study provides a new perspective that antibiotics, e.g. isoniazid, once recognized only to target <italic toggle="yes">Mycobacterium tuberculosis</italic>, can be repurposed as antibiotic adjuvant to tigecycline, expanding our choice of antibiotic&#x02013;antibiotic combinations in treating bacterial infectious diseases.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Tigecycline</kwd><kwd>isoniazid</kwd><kwd>methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></kwd><kwd>proton motive force</kwd><kwd>antibiotic influx</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution><institution-id institution-id-type="doi">10.13039/501100012166</institution-id></institution-wrap></funding-source><award-id>2023YFD1800104</award-id></award-group><award-group><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>32273177</award-id></award-group><award-group><funding-source><institution>Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai)</institution>
</funding-source><award-id>311020006</award-id></award-group><award-group><funding-source><institution-wrap><institution>Science and Technology Planning Project of Guangdong Province</institution><institution-id institution-id-type="doi">10.13039/501100012245</institution-id></institution-wrap></funding-source><award-id>2023B1212060028</award-id></award-group><award-group><funding-source><institution>Fundamental Research Funds for the Central Universities, Sun Yat-sen University</institution>
</funding-source><award-id>24lgzy004</award-id></award-group><funding-statement>This work was supported by the National Key Research and Development Program of China (2023YFD1800104), National Natural Science Foundation of China (No. 32273177), Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) (No. 311020006), Science and Technology Planning Project of Guangdong Province (2023B1212060028), and Fundamental Research Funds for the Central Universities, Sun Yat-sen University (24lgzy004)</funding-statement></funding-group></support-group><counts><fig-count count="6"/><table-count count="0"/><equation-count count="0"/><ref-count count="66"/><page-count count="13"/><word-count count="6615"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S001"><title>Introduction</title><p>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) is one of the notorious bacterial pathogens that are difficult-to-treat in clinic [<xref rid="CIT0001" ref-type="bibr">1</xref>]. MRSA is the primary pathogen leading to skin and soft tissue infections, bacteraemia and joint infection, which are common in community- and hospital-acquired infection [<xref rid="CIT0002" ref-type="bibr">2</xref>]. World Health Organization announced MRSA is one of the six multidrug-resistant pathogens required for urgent attention [<xref rid="CIT0003" ref-type="bibr">3</xref>]. The incidence of MRSA infection is 20&#x02013;30 cases for every 100,000 population in high-income countries each year, and the number is believed to be increasing in recent years [<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref>]. Clinic investigations show that the mortality rate of patients suffered from MRSA infection and infective endocarditis is 17&#x02013;50% [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Meanwhile, MRSA is also a threat to agriculture. The infection of economic animals including pigs, cattle, poultry, and even in aquatic products, poses big economic burden to sustainable agriculture [<xref rid="CIT0007" ref-type="bibr">7&#x02013;9</xref>]. More importantly, MRSA with higher virulence can be transmitted between animals and human beings, threatening human health via food chain [<xref rid="CIT0010" ref-type="bibr">10</xref>]. Thus expanding therapeutic options to treat MRSA infection is urgently required.</p><p>The treatment of MRSA is challenging because of its resistance to a broad spectrum of antibiotics. Vancomycin or teicoplanin, the last line of defence against MRSA, leads to the emergence of corresponding resistant MRSA [<xref rid="CIT0011" ref-type="bibr">11</xref>,<xref rid="CIT0012" ref-type="bibr">12</xref>]. Other antibiotics like tigecycline (TIG), linezolid and daptomycin are also used to treat MRSA, but they have limited therapeutic effects [<xref rid="CIT0013" ref-type="bibr">13</xref>]. Meanwhile, TIG should be used in caution due to its resistance was mainly mediated through efflux pump [<xref rid="CIT0014" ref-type="bibr">14</xref>]. Several studies have indicated the use of TIG, for example, had high frequency of adverse events and is associated with high mortality [<xref rid="CIT0015" ref-type="bibr">15</xref>,<xref rid="CIT0016" ref-type="bibr">16</xref>]. Thus development of method that improves the killing efficacy and decreases side effect is necessary to manage MRSA infection.</p><p>Isoniazid (INA) is a synthetic antibacterial drug with bactericidal effect to <italic toggle="yes">Mycobacterium tuberculosis</italic> (MTB) [<xref rid="CIT0017" ref-type="bibr">17</xref>]. INA has high specificity to inhibit the growth of MTB through disrupting the synthesis of mycobacteric acid, leading to cell wall rupture [<xref rid="CIT0018" ref-type="bibr">18</xref>], but had limited effect to other bacteria [<xref rid="CIT0019" ref-type="bibr">19</xref>]. It has also been shown that INA can be combined with other antibiotics including amikacin, cefotaxime, or imipenem to treat MTB and reduce the occurrence of resistance [<xref rid="CIT0020" ref-type="bibr">20</xref>]. However, the use of INA alone or use with other antibiotics is limited to MTB, whereas research is rarely conducted on whether INA&#x02013;antibiotic combination can be used to treat other types of infection. Here, we find that INA can be used as a TIG adjuvant that potentiates TIG killing efficacy of MRSA, proposing another potential use of INA in clinic.</p></sec><sec sec-type="methods" disp-level="1" id="S002"><title>Materials and methods</title><sec disp-level="2" id="S002-S2001"><title>Bacterial strains and growth conditions</title><p>All clinic MRSA strains were isolated from The Third Affiliated Hospital of Sun Yat-sen University. MRSA strain, ATCC29213, was purchased from American Tissue Culture Center. Strains of <italic toggle="yes">E. coli</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">K. pneumonia</italic> and <italic toggle="yes">S. agalactiae</italic> are our lab stocks [<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>]. To propagate bacterial growth, a single colony was picked up and inoculated into Luria&#x02013;Bertani (LB) medium or brain heart infusion (BHI) medium with shaking.</p></sec><sec disp-level="2" id="S002-S2002"><title>Fractional inhibitory concentration index (FICI) determination</title><p>FICI was determined by checkerboard assays as previously described [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]. Briefly, INA and TIG were serially diluted. Then 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup>&#x02005;CFU/mL bacterial suspensions were added into each well. After culturing at 37&#x000b0;C for 16&#x02005;h, the MICs were recorded as the lowest concentration of drug inhibiting visible growth. The synergistic effect was determined by calculating FIC according to the formula: FICI&#x02009;=&#x02009;MIC<sub>AB</sub>/MIC<sub>A</sub>&#x02009;+&#x02009;MIC<sub>BA</sub>/MIC<sub>B</sub>&#x02009;=&#x02009;FIC<sub>A</sub>&#x02009;+&#x02009;FIC<sub>B</sub>. MIC<sub>A</sub> is the MIC of compound A alone; MIC<sub>AB</sub> is the MIC of compound A in combination with compound B; MIC<sub>B</sub> is the MIC of compound B alone; MIC<sub>BA</sub> is the MIC of compound B in combination with compound A; FIC<sub>A</sub> is the FIC of compound A; FIC<sub>B</sub> is the FIC of compound B. The synergy or additive was defined according to standard criteria (FICI&#x02009;&#x02264;&#x02009;0.5 was defined as synergistic; 0.5&#x02009;&#x0003c;&#x02009;FICI&#x02009;&#x02264;&#x02009;1 was defined as additive; 1&#x02009;&#x0003c;&#x02009;FICI&#x02009;&#x02264;&#x02009;4 was defined as indifference; FICI&#x02009;&#x0003e;&#x02009;4 was defined as antagonism).</p></sec><sec disp-level="2" id="S002-S2003"><title>Antibiotic killing assay</title><p>Antibiotic killing assay was performed as previously described [<xref rid="CIT0025" ref-type="bibr">25</xref>]. Briefly, bacterial cells were collected by centrifugation at 8000&#x02005;rpm for 3&#x02005;min. The samples were then washed with sterile saline three times and resuspended in LB medium, diluted to OD<sub>600</sub> of 0.2 and subjected to a 100-fold dilution, then incubated with INA or/and TIG at 37&#x000b0;C for 6&#x02005;h with shaking. To determine bacterial counts, 100&#x02005;&#x003bc;L of cultures was removed from each treatment and then serially diluted at 10 times in sterile saline buffer. An aliquot of 5&#x02005;&#x003bc;L of each dilution was spotted on LB agar plates and incubated at 37&#x000b0;C for 16&#x02005;h. The dilution containing 20&#x02013;80 colonies would be used to determine the CFU. The percent of survival was calculated based on the CFU of experimental group to control group.</p></sec><sec disp-level="2" id="S002-S2004"><title>Generation of TIG-resistant MRSA</title><p>The generation of antibiotic-resistant MRSA was performed as previously described [<xref rid="CIT0026" ref-type="bibr">26</xref>]. Briefly, a single colony of MRSA7 or MRSA11 was selected and cultured in LB medium at 37&#x000b0;C with shaking. Overnight cultures were transferred into fresh growth medium at 1:100 plus 1/2 MIC TIG of the corresponding strains, e.g. 0.125&#x02005;&#x003bc;g/mL for MRSA7 and 0.25&#x02005;&#x003bc;g/mL for MRSA11, which was cultured at 37&#x000b0;C with shaking. The bacteria was passaged every 24&#x02005;h, and MIC was monitored every three passages. The concentration of TIG in culture medium was adjusted based on the change of MIC. MRSA7-R<sub>TIG</sub> and MRSA11-R<sub>TIG</sub> were obtained when MIC was increased for 32 folds.</p></sec><sec disp-level="2" id="S002-S2005"><title>Preparation of persisters</title><p>The preparation of persisters was performed as previously described [<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref>]. Overnight cultures of MRSA were collected by centrifugation at 8000&#x02005;rpm for 3&#x02005;min. The samples were then washed with sterile saline three times and resuspended in LB medium, then incubated with 5&#x02005;&#x003bc;g/mL ciprofloxacin for 6&#x02005;h. Then, bacteria was treated with higher dose of ciprofloxacin for 4&#x02005;h. Bacterial viability was checked every hour to ensure there is no more bacterial death. Subsequently, persisters were proceeded for antibiotic killing assay.</p></sec><sec disp-level="2" id="S002-S2006"><title>Preparation of biofilm</title><p>Biofilm-formation culture was determined as previously described [<xref rid="CIT0027" ref-type="bibr">27</xref>]. Briefly, 6&#x02005;mm PE50 catheters (0.5&#x02005;mm&#x02009;&#x000d7;&#x02009;1&#x02005;mm) were inoculated in 1&#x02005;mL fresh LB and 10&#x02005;&#x003bc;L cultured stationary phase bacteria, then incubated aerobically for 24&#x02005;h at 37&#x000b0;C. The medium was changed every 24&#x02005;h for a total of 3 days. The PE50 catheters were washed three times with 1&#x02005;mL of sterile saline to remove loosely adherent cells and planktonic cells. Then the catheters were proceeded for antibiotic killing assay.</p></sec><sec disp-level="2" id="S002-S2007"><title>Mice infection experiment</title><p>To evaluate the synergistic effect of INA and TIG <italic toggle="yes">in vivo</italic>, Kunming mice with high genetic heterozygosity was used as previously adopted [<xref rid="CIT0029" ref-type="bibr">29</xref>,<xref rid="CIT0030" ref-type="bibr">30</xref>]. Kunming mice were obtained from the Laboratory Animal Center of Sun Yat-sen University (Guangzhou, China), with an average age of 4 weeks and an average weight of 20&#x02005;g. A total of 40 mice were randomly divided into four groups with 10 mice at each group. Each mice was injected 1&#x02009;&#x000d7;&#x02009;10<sup>8</sup> CFU of MRSA via intraperitoneal injection followed by injection with a single dose of TIG at 10&#x02005;mg/kg, INA at 100&#x02005;mg/kg, or TIG combined with INA. The last group was treated saline buffer as control. At 12&#x02005;h, mouse liver, kidney, and spleen were separately collected and homogenized. Supernatant was used to examine bacterial cells via viable plate counting.</p></sec><sec disp-level="2" id="S002-S2008"><title>Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)</title><p>The determination of MIC was performed as previously described [<xref rid="CIT0031" ref-type="bibr">31</xref>]. To determine MIC, an overnight bacterial culture was diluted 1:100 (v/v) in fresh broth medium and cultured at 37&#x000b0;C to an OD<sub>600</sub> of 0.2. Then cells equivalent to 10<sup>5</sup> CFU were dispensed into each well of a 96-well microtiter polystyrene tray after which a series of twofold dilutions of antibiotic was added. Following incubation at 37&#x000b0;C for 16&#x02005;h, the MIC was defined as the lowest antibiotic concentration that inhibited visible growth. Three biological repeats were carried out.</p><p>The determination of MBC was performed as previously described [<xref rid="CIT0032" ref-type="bibr">32</xref>]. MBC is the lowest concentration that kills 99.9% of bacteria after 24&#x02005;h incubation at 37&#x000b0;C. MBC values were determined by removing 3.5&#x02005;&#x003bc;L of bacterial suspension from the well of MIC plate that has no visible growth and plating in the agar plate to determine CFU. Plates were incubated at 37&#x000b0;C for a total period of 16&#x02005;h. Each experiment was repeated at least three times.</p></sec><sec disp-level="2" id="S002-S2009"><title>Quantification of intracellular TIG</title><p>The quantification of intracellular antibiotic content was performed as previously described [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Briefly, bacteria were incubated with TIG or INA or both at 37&#x000b0;C for 6&#x02005;h and then collected by centrifugation at 8000&#x02005;rpm for 3&#x02005;min. Bacterial pellets were washed three times with sterile saline buffer and resuspended in the same buffer to OD<sub>600</sub>&#x02009;=&#x02009;1.0. A total of 25&#x02005;mL samples were sonicated for 10&#x02005;min, centrifuged and the supernatant was carefully removed to a new tube. Then the sample was diluted, added to the 96-well immunoplates (Cat. 95371O1, CSM, China) coated with 50&#x02005;&#x003bc;L antibody, and incubated at 37&#x000b0;C for 30&#x02005;min. The plates were washed five times and then reacted with 50&#x02005;&#x003bc;L of substrate A solution and B solution at 37&#x000b0;C for 10&#x02005;min in dark. The reaction was stopped by stopping solution. The absorbance at 450&#x02005;nm was measured in a PerkinElmer LS55 Fluorescence Spectrophotometer (PerkinElmer). The quantity of TIG was determined by standard curve. Three biological replicates were included for treatment.</p></sec><sec disp-level="2" id="S002-S2010"><title>Quantitative real-time polymerase chain reaction (qRT-PCR)</title><p>qRT-PCR was carried out as previously described [<xref rid="CIT0031" ref-type="bibr">31</xref>]. 1&#x02005;mL of bacterial culture with OD600&#x02009;=&#x02009;1.0 was harvested. The Trizol (Invitrogen, United States) was used to isolated total RNA of each sample. Then, an EvoM-MLV RT kit with gDNA clean for qPCR (AG11705; Accurate Biotechnology) was used to reverse transcription-PCR. qRT-PCR was performed in 384-well plates with a total volume of 10&#x02005;&#x003bc;L containing 5&#x02005;&#x003bc;L 2&#x000d7; SYBR green premix pro Taq HS qPCR kit (AG11701; Accurate Biotechnology), 2.6&#x02005;&#x003bc;L H2O, 2&#x02005;&#x003bc;L cDNA template, and 0.2&#x02005;&#x003bc;L each of forward and reverse primers (10&#x02005;mM). The primers are listed in Supplementary Table 1. All samples were tested in biological triplicate and run on the LightCycler 480 system (Roche, Germany) according to the manufacturer&#x02019;s instructions, and four independent samples were assayed for both the control group and the test group. The cycling parameters were 95&#x000b0;C for 30 s to activate the polymerase; 40 cycles of 95&#x000b0;C for 10&#x02005;s; and 56&#x000b0;C for 30&#x02005;s. Fluorescence measurements were performed at 72&#x000b0;C for 1&#x02005;s during each cycle. Cycling was terminated at 95&#x000b0;C with a calefactive velocity of 5&#x000b0;C/s to obtain a melting curve. Data are shown as the relative mRNA expression compared with control with the endogenous reference 16S rRNA gene. Primers used in this study are listed in Suppl. Table 1.</p></sec><sec disp-level="2" id="S002-S2011"><title>Propyl iodide (PI) test</title><p>PI staining was performed as previously described [<xref rid="CIT0034" ref-type="bibr">34</xref>]. PI was determined by a Propidium iodide (PI) fluorescent probe (Cat. P3566; Invitrogen, USA). In brief, <italic toggle="yes">MRSA</italic> cells were resuspended to an OD<sub>600</sub> of 0.2 and subjected to a 100-fold dilution, then incubated with INA or/and TIG at 37&#x000b0;C for 6&#x02005;h. After washing with PBS (pH 7.4) three times and resuspending to obtain an OD<sub>600</sub> of 0.2, 1&#x02005;mL bacterial solution was absorbed and divided into 1.5&#x02005;mL EP tubes. 2&#x02005;&#x003bc;g/mL of PI dye solution was added to each tube, thoroughly mixed and incubated at 37&#x000b0;C for 30&#x02005;min in the absence of light. The fluorescence value was determined by a flow cytometry with a wavelength of 544&#x02005;nm and emission light at 620&#x02005;nm.</p></sec><sec disp-level="2" id="S002-S2012"><title>Calcein leakage assay</title><p>Calcein leakage assay was performed as previously described [<xref rid="CIT0034" ref-type="bibr">34</xref>]. Calcein was determined by a polyanionic fluorescein derivative (Cat. C481; Invitrogen, USA). In brief, MRSA cells were resuspended to an OD600 of 0.2 and subjected to a 100-fold dilution, then incubated with INA or/and TIG at 37&#x000b0;C for 6&#x02005;h. After washing with PBS (pH 7.4) three times and resuspending to obtain an OD600 of 0.2, 1&#x02005;mL bacterial solution was absorbed and divided into 1.5&#x02005;mL EP tubes. 2&#x02005;&#x003bc;g/mL of Calcein dye solution was added to each tube, thoroughly mixed and incubated at 37&#x000b0;C for 30&#x02005;min in the absence of light. The fluorescence value was determined by a flow cytometry with a wavelength of 490&#x02005;nm and emission light at 517&#x02005;nm.</p></sec><sec disp-level="2" id="S002-S2013"><title>N-phenyl-1-naphthylamine (NPN) uptake assay</title><p>NPN uptake assay was performed as previously described [<xref rid="CIT0035" ref-type="bibr">35</xref>]. NPN fluorescent probe (Cat. 104043; Sigma, USA). In brief, <italic toggle="yes">MRSA</italic> cells were resuspended to an OD<sub>600</sub> of 0.2 and subjected to a 100-fold dilution, then incubated with INA or/ and TIG at 37&#x000b0;C for 6&#x02005;h. After washing with PBS (pH 7.4) three times and resuspending to obtain an OD<sub>600</sub> of 0.2, 1&#x02005;mL bacterial solution was absorbed and divided into 1.5&#x02005;mL EP tubes. 10&#x02005;&#x003bc;g/mL of NPN dye solution was added to each tube, thoroughly mixed and incubated at 37&#x000b0;C for 30&#x02005;min in the absence of light. The fluorescence value was determined by a fluorescent enzyme labelling instrument with a wavelength of 350&#x02005;nm and emission light at 420&#x02005;nm.</p></sec><sec disp-level="2" id="S002-S2014"><title>Measurement of Membrane Potential</title><p>Membrane potential was measured as previously described [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Bacterial membrane potential was determined by a fluorescent probe DiOC2 [<xref rid="CIT0003" ref-type="bibr">3</xref>] (Cat. M34150; Invitrogen, USA). In brief, <italic toggle="yes">MRSA</italic> cells were resuspended to an OD<sub>600</sub> of 0.2 and subjected to a 100-fold dilution, then incubated with INA or/and TIG at 37&#x000b0;C for 6&#x02005;h. After washing with PBS (pH 7.4) three times and resuspending to obtain an OD<sub>600</sub> of 0.2, 1&#x02005;mL bacterial solution was absorbed and divided into 1.5&#x02005;mL EP tubes. 10&#x02005;&#x003bc;L of 3&#x02005;mM DiOC2 [<xref rid="CIT0003" ref-type="bibr">3</xref>] dye solution was added to each tube, thoroughly mixed and incubated at 37&#x000b0;C for 30&#x02005;min in the absence of light. The fluorescence value was determined by an FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) through a 488&#x02212;530/610&#x02005;nm bandwidth band-pass filter, respectively.</p></sec><sec disp-level="2" id="S002-S2015"><title>Measurement of pH</title><p>pH was measured as previously described [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Bacterial intracellular pH was determined by the pH-sensitive fluorescence probe BCECF-AM (Cat. BL929A, Biosharp, China). In brief, <italic toggle="yes">MRSA</italic> cells were resuspended to an OD<sub>600</sub> of 0.2 and subjected to a 100-fold dilution, then incubated with INA or/and TIG at 37&#x000b0;C for 6&#x02005;h. After washing with PBS (pH 7.4) three times and resuspending to obtain an OD<sub>600</sub> of 0.2, 1&#x02005;mL bacterial solution was absorbed and divided into 1.5&#x02005;mL EP tubes. 10&#x02005;&#x003bc;M BCECF-AM dye solution was added to each tube, thoroughly mixed and incubated at 37&#x000b0;C for 30&#x02005;min in the absence of light. The fluorescence value was determined by an FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) through a 488&#x02212;535&#x02005;nm bandwidth band-pass filter, respectively.</p></sec><sec disp-level="2" id="S002-S2016"><title>Measurement of INA-NAD Adduct</title><p>The formation of INA-NAD adduct was performed as previously described [<xref rid="CIT0037" ref-type="bibr">37</xref>,<xref rid="CIT0038" ref-type="bibr">38</xref>]. Briefly, MRSA cells were resuspended to an OD600 of 0.2 and subjected to a 100-fold dilution, then incubated with INA or/ and TIG at 37&#x000b0;C for 6&#x02005;h. After washing with PBS (pH 7.4) three times and resuspending to obtain an OD600 of 1.0, 20&#x02005;mL bacterial solution was absorbed and divided into 1.5&#x02005;mL EP tubes. And the optical density (OD) of INA-NAD was measured by spectrophotometer (Thermo Scientific NanoDrop). In comparison with the absorption spectrum, increases in absorbance at 300&#x02013;350&#x02005;nm and the A 326/A 278 ratio were used as indicators for the complex formation.</p></sec></sec><sec sec-type="results" disp-level="1" id="S003"><title>Results</title><sec disp-level="2" id="S003-S2001"><title>Isoniazid (INA) potentiates tigecycline (TIG) to methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA)</title><p>To investigate whether INA is able to synergize with different types of antibiotics to treat MRSA infection, we used a clinical isolate of multidrug-resistant MRSA strain, MRSA-7, for the initial screening (Suppl. Figure 1). Fractional inhibitory concentration index (FICI) was used to evaluate the possible synergistic effect of INA with aminoglycosides (gentamycin and kanamycin), &#x003b2;-lactam (ampicillin and cefotaxime), quinolones (ciprofloxacin and ofloxacin), tetracyclines (tetracycline), glycylcycline (tigecycline), lincosamides (lincomycin), and chloramphenicols (chloramphenicol). The combination was evaluated, where FICI&#x02009;&#x02264;&#x02009;0.5, 0.5&#x02009;&#x0003c;&#x02009;FICI&#x02009;&#x0003c;&#x02009;1, FICI&#x02009;=&#x02009;1, 1&#x02009;&#x0003c;&#x02009;FICI&#x02009;&#x0003c;&#x02009;4, and FICI&#x02009;&#x02265;&#x02009;4 were considered as synergism, partial synergism, additivity, indifference, and antagonism, respectively [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]. INA was synergized with TIG, while was partially synergized with aminoglycosides, tetracycline and lincomycin, and had no effect on other antibiotics (<xref rid="F0001" ref-type="fig">Figure 1</xref>A).
<fig position="float" id="F0001"><label>Figure 1.</label><caption><p>INA potentiates TIG to eliminate MRSA. (A) The FICI of INA combined with different types of antibiotics. (B) The FICI of INA combined with TIG to different MRSA strains. (C) The MIC of MRSA to TIG in the presence of 1/2 MIC of INA. INA, isoniazid; GEN, gentamycin; KAN, kanamycin; AMP, ampicillin; CFT, ceftaxime; CIP, ciprofloxacin; OFX, ofloxacin; TET, tetracycline; TIG, tigecycline; LIN, lincomycin; CM, chloramphenicol.</p></caption><alternatives><graphic xlink:href="TEMI_A_2434587_F0001_OB" content-type="black-white" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2434587_F0001_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>To further confirm the synergistic effect of INA and TIG, we treated 1 standard strain of MRSA, ATCC29213 and 10 clinic multidrug-resistant isolates of MRSA with INA plus TIG and (see Suppl. Figure 1). INA and TIG were synergistic for 8 of the 11 strains and were partial synergistic for another 3 strains (<xref rid="F0001" ref-type="fig">Figure 1</xref>B). Furthermore, we measured the MIC of the MRSA strains to TIG in the presence of INA. The presence of 1/2 MIC INA decreased the MIC of MRSA to TIG for 4&#x02013;128 folds (<xref rid="F0001" ref-type="fig">Figure 1</xref>C). To investigate whether INA plus TIG had effect on strains with higher tigecycline resistance, the strains of MRSA7 and MRSA11 were propagated to generate tigecycline-resistant strains, MRSA7-R<sub>TIG</sub> and MRSA11-R<sub>TIG</sub>, whose MIC to TIG was increased to 8 and 16&#x02005;&#x003bc;g/mL, respectively, being 32 folds of increase (see Suppl. Figure 2A). Being consistent, the presence of INA decreased the MIC for 16 folds for both of the strains (see Suppl. Figure 2A).</p><p>Furthermore, we tested the synergistic effects of INA and TIG to other bacterial pathogens including Gram-negative pathogens, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Klebsiella pneumonia</italic>, and <italic toggle="yes">Pseudomonas aeruginosa</italic>, and Gram-positive pathogens <italic toggle="yes">Bacillus subtilis</italic>, <italic toggle="yes">Enterococcus faecium,</italic> and <italic toggle="yes">Streptococcus agalactiae</italic>. Interestingly, INA and TIG showed good synergistic effect against all of the three <italic toggle="yes">E. coli</italic> strains, 1 strain of <italic toggle="yes">B. subtilis</italic> and 3 out of 6 strains of <italic toggle="yes">E. faecium</italic> but only partially synergistic to other pathogens (see Suppl. Figure 2B). Thus we only focused on MRSA in this study.</p></sec><sec disp-level="2" id="S003-S2002"><title>INA and TIG eliminate MRSA infection <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></title><p>To further analyse the synergistic effect of INA and TIG, we treated the strain, MRSA11, with sublethal dose of TIG and INA. When fixed at 0.04&#x02005;&#x003bc;g/mL TIG, the viability of MRSA was decreased along with the increasing concentration of INA in a dose-dependent manner (<xref rid="F0002" ref-type="fig">Figure 2</xref>A), where INA had no killing effect at all tested concentrations. Since INA at 8 and 16&#x02005;mM had similar potentiation effect, we chose 8&#x02005;mM INA for the following studies (<xref rid="F0002" ref-type="fig">Figure 2</xref>A). Similarly, when the concentration INA was fixed at 8&#x02005;mM, the viability of MRSA was reduced in a dose-dependent manner (<xref rid="F0002" ref-type="fig">Figure 2</xref>B). TIG alone failed to kill MRSA at all tested concentrations. Furthermore, the synergistic effect of INA and TIG was tested in a time-dependent killing assay. If incubated for 8&#x02005;h or longer, INA increased TIG killing for 3998 folds (<xref rid="F0002" ref-type="fig">Figure 2</xref>C). This potentiation suggests that INA may reduce the dosage of TIG that can achieve the same effect. Thus we determined the combination index (CI) and dose-reduction index (DRI) of the INA and TIG combinations. CI indicates the combining effect of drugs, where CI&#x02009;&#x0003c;&#x02009;1 is considered as synergistic. The CI values for all the combinations of INA and TIG are less than 1, suggestion synergy (see Suppl. Figure 3A). DRI represents the fold of reduced dose when a drug is used in combination with another drug to achieve the same efficacy (Fa) as the drug alone, where DRI&#x02009;&#x0003e;&#x02009;1 is favourable [<xref rid="CIT0025" ref-type="bibr">25</xref>,<xref rid="CIT0039" ref-type="bibr">39</xref>]. As such, we only considered Fa&#x02009;&#x0003e;&#x02009;0.95, where the dosage of TIG was reduced at least nine folds in the presence of INA (see Suppl. Figure 3B). These data suggest that INA may reduce the dosage of TIG to treat MRSA infection.
<fig position="float" id="F0002"><label>Figure 2.</label><caption><p>INA and TIG eliminate MRSA infection <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. (A) Percent survival of MRSA11 in the presence of the increasing concentration of INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (B) Percent survival of MRSA11 in the presence of the increasing concentration of TIG plus 8&#x02005;mM INA. (C) Percent survival of MRSA11 in the presence of 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG at indicated incubation time points. (D) Percent survival of persister in the presence of INA plus TIG. (E) Percent survival of biofilm in the presence of INA plus TIG. (F) Bacterial loads of mice infected with MRSA in the presence or absence of INA, TIG or both. Results are displayed as mean&#x02009;&#x000b1;&#x02009;standard errors of the means (SEM) (<italic toggle="yes">N</italic>&#x02009;&#x02265;&#x02009;3 technical replicates per sample), and statistically significant differences are identified by Student&#x02019;s <italic toggle="yes">t</italic> test. *, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01. Each experiment was repeated independently at least three times.</p></caption><alternatives><graphic xlink:href="TEMI_A_2434587_F0002_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2434587_F0002_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>MRSA infection is always accompanied with persister and biofilm. To investigate whether INA could potentiate TIG on these two situations. MRSA11 was prepared as persister. When TIG was at either 0.02 or 0.04&#x02005;&#x003bc;g/mL, persister cannot be eliminated. Whereas the supplementation of INA could increase the killing of persister for 3045 folds (<xref rid="F0002" ref-type="fig">Figure 2</xref>D). Similar results were observed for the killing of biofilm, where the biofilm cannot be killed by TIG alone even the concentration was increased for 520 folds. However, INA facilitates the killing (<xref rid="F0002" ref-type="fig">Figure 2</xref>E).</p><p>To investigate such synergistic effect works <italic toggle="yes">in vivo</italic>, bacterial loads were monitored in different tissue of mice. After bacterial challenge, the treatment of saline, INA or TIG alone could not or only slightly reduced bacterial loads in liver, kidney and spleen, but when both of INA and TIG were present, the bacterial loads were significantly reduced in the tissues (<xref rid="F0002" ref-type="fig">Figure 2</xref>F). These data together suggest that INA potentiate TIG killing both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>.</p></sec><sec disp-level="2" id="S003-S2003"><title>INA enhances TIG bacteriostatic activity</title><p>TIG is known as bacteriostatic antibiotic by stalling cellular activity but not directly causing cell death [<xref rid="CIT0040" ref-type="bibr">40</xref>]. But higher concentration of bacteriostatic antibiotic can cause cell death [<xref rid="CIT0041" ref-type="bibr">41</xref>]. To explore whether INA affects TIG bacteriostatic activity, we measured the minimal bactericidal concentration (MBC) of INA on TIG using the MRSA11. The MIC of MRSA11 to TIG was 0.5&#x02005;&#x003bc;g/mL, and the MBC was 8&#x02005;&#x003bc;g/mL. The difference between MIC and MBC was 16 folds, confirming that TIG was bacteriostatic antibiotics. Whereas the presence of INA at 8&#x02005;mM decreased MIC of MRSA11 from 0.5 to 0.25&#x02005;&#x003bc;g/mL, and the MBC of TIG dropped from 8 to 2&#x02005;&#x003bc;g/mL, where the difference was four folds (<xref rid="F0003" ref-type="fig">Figure 3</xref>A). These data suggest that TIG is a bacteriostatic antibiotic even in the presence of INA.
<fig position="float" id="F0003"><label>Figure 3.</label><caption><p>INA enhances TIG bacteriostatic activity. (A) MIC and MBC of MRSA11 in the presence or absence of INA. (B) Percent of cells having PI of MRSA11 in the absence or presence of INA plus TIG. (C) Percent of cells having calcein of MRSA11 in the absence or presence of INA plus TIG. (D) Scanning electron micrographs of MRSA11 being treated with INA, TIG, or both (Scalar bar&#x02009;=&#x02009;1, 2, 10&#x02005;&#x003bc;m, respectively). Results are displayed as mean&#x02009;&#x000b1;&#x02009;standard errors of the means (SEM) (<italic toggle="yes">N</italic>&#x02009;&#x02265;&#x02009;3 technical replicates per sample), and statistically significant differences are identified by Student&#x02019;s <italic toggle="yes">t</italic> test. *, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01. Each experiment was repeated independently at least three times.</p></caption><alternatives><graphic xlink:href="TEMI_A_2434587_F0003_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2434587_F0003_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>The antimicrobial activity of INA and TIG was further analysed at cellular level. Membrane permeability was investigated with propidium iodide (PI), which can only cross the dead cell [<xref rid="CIT0042" ref-type="bibr">42</xref>]. Treatment with TIG or INA alone had few PI positive cells, while the number of PI positive cells was increased when supplemented with both of TIG and INA (<xref rid="F0003" ref-type="fig">Figure 3</xref>B). Calcein leakage assay can be used to determine the membrane integrity [<xref rid="CIT0043" ref-type="bibr">43</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>]. Similarly, TIG had no effect of calcein leakage. TIG alone reduced calcein positive cell, while INA plus TIG further decreased the number of calcein positive cell (<xref rid="F0003" ref-type="fig">Figure 3</xref>C). In addition, scanning electron microscope (SEM) analysis showed that the INA or TIG had no obvious effect on membrane structure, whereas the INA plus TIG cause membrane rupture, and even some bacteria membrane was broken (<xref rid="F0003" ref-type="fig">Figure 3</xref>D). These data together suggest that INA enhances the killing of TIG to MRSA and possibly through membrane integrity.</p></sec><sec disp-level="2" id="S003-S2004"><title>INA enhances intracellular accumulation of TIG</title><p>Intracellular concentration of antibiotics is crucial for antibiotic function. To investigate whether INA could enhance antibiotic influx into bacteria, we first determined the change of membrane permeability. MRSA uptake of N-phenyl-1-napthylamine (NPN), a fluorescence probe, was performed in the presence of INA, TIG or both. Treating MRSA11 with INA or TIG alone slightly increased NPN uptake, whereas when both of INA and TIG were present, the uptake was increased for 2.83 folds (<xref rid="F0004" ref-type="fig">Figure 4</xref>A). Thus we determined the intracellular TIG concentration. Similar to the NPN uptake assay, intracellular concentration of TIG was highest in the bacteria being treated with INA and TIG as compared to TIG alone (<xref rid="F0004" ref-type="fig">Figure 4</xref>B). Furthermore, intracellular concentration of TIG was increased along with the increasing extracellular concentrations of TIG and the presence of INA increased intracellular TIG (<xref rid="F0004" ref-type="fig">Figure 4</xref>C). Similarly, intracellular TIG was also increased in a time-dependent manner and was enhanced by the presence of INA (<xref rid="F0004" ref-type="fig">Figure 4</xref>D). These results demonstrate that INA enhanced TIG accumulation in the bacteria.
<fig position="float" id="F0004"><label>Figure 4.</label><caption><p>INA enhances intracellular accumulation of TIG. (A) NPN fluorescence intensity of MRSA11 in the presence or absence of 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (B) Intracellular TIG of MRSA11 being treated with indicated concentrations of 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (C) Intracellular TIG of MRSA11 being treated with INA plus the increasing concentration of TIG. (D) Intracellular TIG of MRSA11 being treated with INA plus TIG at the indicated incubation periods. (E) pH fluorescence intensity of MRSA11 in the presence or absence of 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (F) Percent survival of MRSA11 in the presence of the increasing concentration of AS with INA plus TIG. (G) Membrane potential of MRSA11 in the presence or absence of 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (H, I) Percent survival of MRSA11 in the presence of the increasing concentration of CCCP with INA plus TIG. (J) qRT-PCR for expression of <italic toggle="yes">mepA</italic> of MRSA11 in the absence and presence of INA plus TIG. Results are displayed as mean&#x02009;&#x000b1;&#x02009;standard errors of the means (SEM) (<italic toggle="yes">N</italic>&#x02009;&#x02265;&#x02009;3 technical replicates per sample), and statistically significant differences are identified by student&#x02019;s <italic toggle="yes">t</italic> test. *, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01. Each experiment was repeated independently at least three times.</p></caption><alternatives><graphic xlink:href="TEMI_A_2434587_F0004_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2434587_F0004_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>Intracellular TIG concentration was affected by dynamic antibiotic influx and efflux. Proton motive force (PMF) plays critical roles in regulating TIG dynamics in bacteria, which is composed of two components, a transmembrane electrical potential and a transmembrane pH gradient [<xref rid="CIT0045" ref-type="bibr">45</xref>]. pH gradient regulates TIG influx whereas membrane potential enhances TIG efflux [<xref rid="CIT0046" ref-type="bibr">46</xref>,<xref rid="CIT0047" ref-type="bibr">47</xref>]. To investigate whether INA affects these two components. MRSA was treated with TIG or INA or both. For pH gradient, the fluorescence intensity was slightly increased by TIG or INA but was significantly increased by both, suggesting enhanced influx of TIG in the presence of INA (<xref rid="F0004" ref-type="fig">Figure 4</xref>E). Ammonia sulphate (AS), which disrupts the pH gradient, decreased the synergistic effect of TIG and INA in a dose-dependent manner (<xref rid="F0004" ref-type="fig">Figure 4</xref>F).</p><p>In the contrast, the membrane potential showed a completely different pattern. INA alone decreased the membrane potential while TIG increased the membrane potential. More importantly, INA counteracted the increased potential induced by TIG, lower than the non-treated control (<xref rid="F0004" ref-type="fig">Figure 4</xref>G). Carbonyl-cyanide 3-chlorophenylhydrzone (CCCP) is a known chemical to abrogate membrane potential [<xref rid="CIT0048" ref-type="bibr">48</xref>,<xref rid="CIT0049" ref-type="bibr">49</xref>]. The treatment of MRSA with CCCP enhanced TIG killing in a dose-dependent manner, confirming INA-decreased PMF were critical for TIG killing (<xref rid="F0004" ref-type="fig">Figure 4</xref>H). And CCCP had additive effect to INA on TIG killing activity than CCCP alone (<xref rid="F0004" ref-type="fig">Figure 4</xref>I). In addition, MepA, encoded by <italic toggle="yes">mepA</italic>, is an efflux pump in MRSA, whose overexpression or mutation causes TIG resistance [<xref rid="CIT0050" ref-type="bibr">50</xref>]. When quantified the gene expression of this gene, TIG treatment significantly increased <italic toggle="yes">mepA</italic> expression but not by INA alone. Interestingly, INA plus TIG had no significant effect on the expression as compared to TIG (<xref rid="F0004" ref-type="fig">Figure 4</xref>J). Thus TIG increases <italic toggle="yes">mep</italic> expression but not affected by the presence of INA. For other efflux pumps in <italic toggle="yes">S. aureus</italic> that had not yet reported to confer TIG resistance, only the expression of <italic toggle="yes">norA</italic> and <italic toggle="yes">norB</italic> (efflux pumps for fluoroquinolones in MRSA), MDR and <italic toggle="yes">tet38</italic> were increased by TIG but not further boosted by INA (see Suppl. Figure 4). These data together suggest that INA promotes intracellular TIG accumulation by promoting drug influx but limiting efflux dependent on PMF.</p></sec><sec disp-level="2" id="S003-S2005"><title>INA plus TIG destabilize cellular membrane to promote TIG accumulation</title><p>To explore how INA plus TIG promote TIG accumulation, we first determine the formation of INA-NAD adduct, a functional form of INA. As compared to TIG alone, INA or INA plus TIG increased the formation of INA-NAD, where INA plus TIG induced higher levels of adduct (<xref rid="F0005" ref-type="fig">Figure 5</xref>A). INA-NAD is highly reactive and could damage different cellular structure [<xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>]. Our above results suggest that INA plus TIG alter membrane permeability (<xref rid="F0003" ref-type="fig">Figures 3</xref>C and D). The addition of phosphatidylethanolamine (PE) and cardiolipin (CL), the key components of phospholipids in bacterial membrane abrogating the effect of membrane-targeting drugs [<xref rid="CIT0047" ref-type="bibr">47</xref>,<xref rid="CIT0051" ref-type="bibr">51</xref>], could decrease membrane permeability that was induced by INA plus TIG, where the percent of PI positive cells was dropped from 18.32% to 7.44% by PE and to 3.08% by CL (<xref rid="F0005" ref-type="fig">Figure 5</xref>B). Similarly, PE and CL also reduced NPN by INA and TIG (<xref rid="F0005" ref-type="fig">Figure 5</xref>C). Being consistently, PE and CL increased bacterial survival for 228.3 and 114.17 folds in the presence of both of INA and TIG (<xref rid="F0005" ref-type="fig">Figures 5</xref>D and E). However, PE and CL had limited protective effects to TIG. Furthermore, when bacteria were treated with INA plus TIG in the presence of PE and CL, PE and CL decreased intracellular TIG concentration to a similar level of TIG alone (<xref rid="F0005" ref-type="fig">Figure 5</xref>F). Moreover, the PE and CL abrogated INA-induced change on membrane potential and pH, suggesting bacteria restore resistance to TIG. Importantly, INA didn&#x02019;t interact with PE and CL as assayed by ITC (see Suppl. Figure 5). Taken together, these data suggest that INA form INA-NAD adduct that destabilize membrane to allow the influx but limit efflux of TIG (<xref rid="F0006" ref-type="fig">Figure 6</xref>).
<fig position="float" id="F0005"><label>Figure 5.</label><caption><p>INA plus TIG destabilize cellular membrane to promote TIG accumulation. (A) INA-NAD adduct of MRSA11 in the presence or absence of 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (B) Percent of cells having PI of MRSA11 in the absence or presence of PE or CL with 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (C) NPN fluorescence intensity of MRSA11 in the absence or presence of PE or CL with 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (D, E) Percent survival of MRSA11 in the absence or presence of PE or CL with 8&#x02005;mM INA plus 0.04&#x02005;&#x003bc;g/mL TIG. (F) Intracellular TIG of MRSA11 in the absence or presence of PE or CL with INA plus TIG. Results are displayed as mean&#x02009;&#x000b1;&#x02009;standard errors of the means (SEM) (<italic toggle="yes">N</italic>&#x02009;&#x02265;&#x02009;3 technical replicates per sample), and statistically significant differences are identified by student&#x02019;s <italic toggle="yes">t</italic> test. *, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01. Each experiment was repeated independently at least three times.</p></caption><alternatives><graphic xlink:href="TEMI_A_2434587_F0005_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2434587_F0005_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig>
<fig position="float" id="F0006"><label>Figure 6.</label><caption><p>Proposed model. INA enhances the TIG influx to enhance intracellular TIG accumulation to combat MRSA infection.</p></caption><alternatives><graphic xlink:href="TEMI_A_2434587_F0006_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2434587_F0006_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p></sec></sec><sec sec-type="discussion" disp-level="1" id="S004"><title>Discussion</title><p>The rising of antibiotic resistance has been subjected to big concerns both in academic and society. The urgent need for the development of strategies in dealing with the situation leads to two major routes, the discovery of new antibiotics and the search for antibiotic adjuvants that potentiate current available antibiotics [<xref rid="CIT0052" ref-type="bibr">52</xref>,<xref rid="CIT0053" ref-type="bibr">53</xref>]. Antibiotic combinations are of such strategy that is believed to rejuvenate the efficacy of antibiotics to which bacteria have developed resistance, avoid toxicity but getting greater therapeutic effect, and shorten the duration of therapy but with fast and low-cost development [<xref rid="CIT0054" ref-type="bibr">54</xref>].</p><p>In this study, we exploit the antibiotic combinations of INA and TIG in treating MRSA. INA is a prodrug that is converted to its active form through KatG, catalase-peroxidase enzyme, in MTB [<xref rid="CIT0055" ref-type="bibr">55</xref>]. The active form of INA can affect multiple cellular process that contributes to bactericidal activity of INA [<xref rid="CIT0019" ref-type="bibr">19</xref>]. Although <italic toggle="yes">katG</italic> gene is widely present across different bacterial species, INA has poor activity against other types of bacterial pathogens. Meanwhile, it is possible that using INA as a molecule to remodel bacterial metabolism to enhance the activity of other types of antibiotics. Thus we explore such possibility by testing the combination of INA with various types of antibiotics, and we found it synergize best with TIG. TIG belongs to the tetracycline class that can be used to treat polymicrobial multidrug-resistant infection by both of gram-positive and gram-negative bacteria [<xref rid="CIT0016" ref-type="bibr">16</xref>]. TIG has been proved to be effective against not only MRSA but also vancomycin-resistant <italic toggle="yes">enterococci</italic>, and extended-spectrum &#x003b2;-lactamase (ESBL)-producing <italic toggle="yes">Enterobacteriaceae</italic> [<xref rid="CIT0056" ref-type="bibr">56</xref>]. A recent meta-analysis of TIG resistance in MRSA suggests that TIG should be used in caution to prevent the occurrence of more resistance [<xref rid="CIT0013" ref-type="bibr">13</xref>], e.g. 3% resistance rate of MRSA in India and 53.5% isolates of <italic toggle="yes">S. aureus</italic> are non-susceptible to TIG [<xref rid="CIT0057" ref-type="bibr">57</xref>]. Thus the identification of INH as an antibiotic adjuvant is expected to increase the lifespan of TIG in clinic.</p><p>The doses we used in this study are clinic relevant. Our bacterial challenge assay employs 10&#x02005;mg/kg TIG or/and 100&#x02005;mg/kg INA. The dose used in mouse can be translated into human dose based on surface area with a coefficient of 0.081 [<xref rid="CIT0058" ref-type="bibr">58</xref>]. Thus the corresponding dose used in mice is equivalent of 0.81&#x02005;mg/kg for TIG or/and 8.1&#x02005;mg/kg for INA. The recommended dose regimen for TIG is 100&#x02005;mg at initial dose and followed by 50&#x02005;mg for every 12&#x02005;h [<xref rid="CIT0056" ref-type="bibr">56</xref>]. To treat MTB in children, patients received 10.2&#x02005;mg/kg for intermittent regimen or 8.4&#x02005;mg/kg for daily regimen [<xref rid="CIT0059" ref-type="bibr">59</xref>]. The standard dose of INA used in adult is 5&#x02013;15&#x02005;mg/kg depending on the duration of treatment [<xref rid="CIT0060" ref-type="bibr">60</xref>]. Moreover, INA may also act through immune system to facilitate the elimination of MTB infection. INA induces progenitor stem cell differentiate into pro-inflammatory monocytes, thus increasing monocyte population, and strengthen the immune competency of granuloma [<xref rid="CIT0061" ref-type="bibr">61</xref>]. Additionally, INA-induced autophagy in infected immune cell, and inhibiting IL-1R1 and TNF signalling are required for the antimycobacterial function of INA [<xref rid="CIT0062" ref-type="bibr">62</xref>,<xref rid="CIT0063" ref-type="bibr">63</xref>]. However, whether INA in combing with TIG also act through immune system, and whether INA has a broad immune response-promoting effects should be explored.</p><p>Antibiotic influx is the key to reverse antibiotic resistance. We demonstrate that INA drive the TIG influx into the bacteria that are the key to enhance the antibacterial activity of TIG. Removing the membrane barrier to allow the antibiotic enter into the cell is considered as a major challenge in combating antibiotic resistance because of antibiotic-resistant bacteria has low cell permeability [<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0064" ref-type="bibr">64</xref>]. The rational design of small molecule, e.g. colistin, to disrupt is believed to enhance the killing of bacteria [<xref rid="CIT0065" ref-type="bibr">65</xref>]. Our study suggests that INA itself has low toxicity to MRSA and can be a potential TIG adjuvant to MRSA infection. Furthermore, the recent advance on metabolic regulation of antibiotic resistance also enlightens the use of metabolites to promote antibiotic influx. Alanine, glucose, fructose, glutamate and pyruvate enhance intracellular accumulation of aminoglycosides through the pyruvate cycle [<xref rid="CIT0064" ref-type="bibr">64</xref>,<xref rid="CIT0066" ref-type="bibr">66</xref>]. Glutamine and fructose promote &#x003b2;-lactams influx into the cell [<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0033" ref-type="bibr">33</xref>]. Although these studies were performed mainly in gram-negative bacteria, this study that developing approach to enhance intracellular antibiotic accumulation is also key to combat MRSA infection.</p><p>Although we demonstrate that INA and TIG are potential on eliminating MRSA infection in a mouse infection model, we have to note that this infection model only represents bacteraemia. MRSA also commonly causes other infection like skin and soft tissue, and joint infections. Despite that the synergistic effect should be investigated in different infection model to show its use in different clinic settings in the future, we do believe the boosting effect of INA to TIG. The reason is because of the mechanism that INA mainly promotes MRSA uptake of TIG. A previous study showed that glutamine increased bacteria uptake of ampicillin that help mouse defence against different bacterial pathogens [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Thus INA and TIG could also be possibly effective against MRSA infection in other clinic-relevant situation.</p><p>In conclusion, our study identifies INA is not only an anti-MTB antibiotic but also can be explored as an antibiotic adjuvant to antibiotics to kill non-MTB bacterial pathogens. And the main function of INA in revering antibiotic resistance of MRSA is to enhance the TIG influx. Thus our study suggests a new approach to control MRSA infection through antibiotic combinations.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM5690" position="float" content-type="local-data"><caption><title>Supplementary Materials.docx</title></caption><media xlink:href="TEMI_A_2434587_SM5690.docx"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We thank Ms. Daifen Huang for the maintenance of animals for this study.</p></ack><sec sec-type="author-contributions" disp-level="1" id="S005"><title>Author contribution</title><p>BP conceptualized the idea and designed the project. XWC, HQC, JHW, ZHW, and SQT performed experiments. XWC, HQC, JHW, ZHW, and SQT performed data analysis. BP and XWC interpreted data. BP wrote the manuscript. All authors have reviewed the manuscript and acknowledged their contributions.</p></sec><sec disp-level="1" id="S006"><title>Ethical approval</title><p>The protocol to perform animal study has been reviewed and approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (approval no. SYSU-IACUC &#x02013; 2020-B1267).</p></sec><sec sec-type="COI-statement" disp-level="1" id="S007"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="supplementary-material" id="S000"><title>Supplemental Material</title><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="10.1080/22221751.2024.2434587" ext-link-type="doi">https://doi.org/10.1080/22221751.2024.2434587</ext-link>.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carmeli</surname>
<given-names>Y.</given-names></string-name></person-group>
<article-title>Strategies for managing today&#x02019;s infections</article-title>. <source>Clin Microbiol Infect</source>. <year>2008</year>;<volume>14</volume>(<issue>Suppl. 3</issue>):<fpage>22</fpage>&#x02013;<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1469-0691.2008.01957.x</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turner</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Sharma-Kuinkel</surname>
<given-names>BK</given-names></string-name>, <string-name><surname>Maskarinec</surname>
<given-names>SA</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>: an overview of basic and clinical research</article-title>. <source>Nat Rev Microbiol</source>. <year>2019</year>;<volume>17</volume>(<issue>4</issue>):<fpage>203</fpage>&#x02013;<lpage>218</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41579-018-0147-4</pub-id><pub-id pub-id-type="pmid">30737488</pub-id>
</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romanescu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Oprean</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lombrea</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Current state of knowledge regarding WHO high priority pathogens-resistance mechanisms and proposed solutions through candidates such as essential oils: a systematic review</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>11</issue>):<fpage>9727</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms24119727</pub-id><pub-id pub-id-type="pmid">37298678</pub-id>
</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barrasa-Villar</surname>
<given-names>JI</given-names></string-name>, <string-name><surname>Aibar-Remon</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Prieto-Andres</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms</article-title>. <source>Clin Infect Dis</source>. <year>2017</year>;<volume>65</volume>(<issue>4</issue>):<fpage>644</fpage>&#x02013;<lpage>652</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cix411</pub-id><pub-id pub-id-type="pmid">28472416</pub-id>
</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shimizu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mihara</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ohara</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Relationship between mortality and molecular epidemiology of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> bacteremia</article-title>. <source>PLoS One</source>. <year>2022</year>;<volume>17</volume>(<issue>7</issue>):<fpage>e0271115</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0271115</pub-id><pub-id pub-id-type="pmid">35802589</pub-id>
</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Inagaki</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lucar</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Blackshear</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Methicillin-susceptible and methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> bacteremia: nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the United States</article-title>. <source>Clin Infect Dis</source>. <year>2019</year>;<volume>69</volume>(<issue>12</issue>):<fpage>2112</fpage>&#x02013;<lpage>2118</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciz123</pub-id><pub-id pub-id-type="pmid">30753447</pub-id>
</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaiyapuri</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Joseph</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>BM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> in seafood: prevalence, laboratory detection, clonal nature, and control in seafood chain</article-title>. <source>J Food Sci</source>. <year>2019</year>;<volume>84</volume>(<issue>12</issue>):<fpage>3341</fpage>&#x02013;<lpage>3351</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1750-3841.14915</pub-id><pub-id pub-id-type="pmid">31769517</pub-id>
</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lowder</surname>
<given-names>BV</given-names></string-name>, <string-name><surname>Guinane</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Ben Zakour</surname>
<given-names>NL</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Recent human-to-poultry host jump, adaptation, and pandemic spread of <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2009</year>;<volume>106</volume>(<issue>46</issue>):<fpage>19545</fpage>&#x02013;<lpage>19550</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0909285106</pub-id><pub-id pub-id-type="pmid">19884497</pub-id>
</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hamid</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bhat</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Mir</surname>
<given-names>IA</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Phenotypic and genotypic characterization of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> from bovine mastitis</article-title>. <source>Vet World</source>. <year>2017</year>;<volume>10</volume>(<issue>3</issue>):<fpage>363</fpage>&#x02013;<lpage>367</lpage>. doi:<pub-id pub-id-type="doi">10.14202/vetworld.2017.363-367</pub-id><pub-id pub-id-type="pmid">28435202</pub-id>
</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davies</surname>
<given-names>PR</given-names></string-name>, <string-name><surname>Alexander</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Bender</surname>
<given-names>JB</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Livestock density as risk factor for livestock-associated methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>, the Netherlands</article-title>. <source>Emerg Infect Dis</source>. <year>2013</year>;<volume>19</volume>(<issue>9</issue>):<fpage>1551</fpage>&#x02013;<lpage>1552</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid1909.121577</pub-id><pub-id pub-id-type="pmid">23968678</pub-id>
</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilhelm</surname>
<given-names>MP.</given-names></string-name></person-group>
<article-title>Vancomycin</article-title>. <source>Mayo Clin Proc</source>. <year>1991</year>;<volume>66</volume>(<issue>11</issue>):<fpage>1165</fpage>&#x02013;<lpage>1170</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0025-6196(12)65799-1</pub-id><pub-id pub-id-type="pmid">1943250</pub-id>
</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muhlberg</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Umstatter</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Kleist</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria</article-title>. <source>Can J Microbiol</source>. <year>2020</year>;<volume>66</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1139/cjm-2019-0309</pub-id><pub-id pub-id-type="pmid">31545906</pub-id>
</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shariati</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dadashi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chegini</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The global prevalence of daptomycin, tigecycline, quinupristin/dalfopristin, and linezolid-resistant <italic toggle="yes">Staphylococcus aureus</italic> and coagulase-negative staphylococci strains: a systematic review and meta-analysis</article-title>. <source>Antimicrob Resist Infect Control</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>56</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13756-020-00714-9</pub-id><pub-id pub-id-type="pmid">32321574</pub-id>
</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Cai</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The emergence of clinical resistance to tigecycline</article-title>. <source>Int J Antimicrob Agents</source>. <year>2013</year>;<volume>41</volume>(<issue>2</issue>):<fpage>110</fpage>&#x02013;<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.09.005</pub-id><pub-id pub-id-type="pmid">23127485</pub-id>
</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prasad</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Danner</surname>
<given-names>RL</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Excess deaths associated with tigecycline after approval based on noninferiority trials</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>;<volume>54</volume>(<issue>12</issue>):<fpage>1699</fpage>&#x02013;<lpage>1709</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cis270</pub-id><pub-id pub-id-type="pmid">22467668</pub-id>
</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tasina</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Haidich</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Kokkali</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis</article-title>. <source>Lancet Infect Dis</source>. <year>2011</year>;<volume>11</volume>(<issue>11</issue>):<fpage>834</fpage>&#x02013;<lpage>844</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(11)70177-3</pub-id><pub-id pub-id-type="pmid">21784708</pub-id>
</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fernandes</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Salgado</surname>
<given-names>HRN</given-names></string-name>, <string-name><surname>Santos</surname>
<given-names>JLD.</given-names></string-name></person-group>
<article-title>Isoniazid: a review of characteristics, properties and analytical methods</article-title>. <source>Crit Rev Anal Chem</source>. <year>2017</year>;<volume>47</volume>(<issue>4</issue>):<fpage>298</fpage>&#x02013;<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10408347.2017.1281098</pub-id><pub-id pub-id-type="pmid">28080136</pub-id>
</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Timmins</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Deretic</surname>
<given-names>V.</given-names></string-name></person-group>
<article-title>Mechanisms of action of isoniazid</article-title>. <source>Mol Microbiol</source>. <year>2006</year>;<volume>62</volume>(<issue>5</issue>):<fpage>1220</fpage>&#x02013;<lpage>1227</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05467.x</pub-id><pub-id pub-id-type="pmid">17074073</pub-id>
</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Unissa</surname>
<given-names>AN</given-names></string-name>, <string-name><surname>Subbian</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hanna</surname>
<given-names>LE</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Overview on mechanisms of isoniazid action and resistance in <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Infect Genet Evol</source>. <year>2016</year>;<volume>45</volume>:<fpage>474</fpage>&#x02013;<lpage>492</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.meegid.2016.09.004</pub-id><pub-id pub-id-type="pmid">27612406</pub-id>
</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yilancioglu</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Cokol</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Design of high-order antibiotic combinations against <italic toggle="yes">M. tuberculosis</italic> by ranking and exclusion</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>11876</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-019-48410-y</pub-id><pub-id pub-id-type="pmid">31417151</pub-id>
</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>XW</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>YL</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Fructose promotes ampicillin killing of antibiotic-resistant <italic toggle="yes">Streptococcus agalactiae</italic></article-title>. <source>Virulence</source>. <year>2023</year>;<volume>14</volume>(<issue>1</issue>):2180938. doi:<pub-id pub-id-type="doi">10.1080/21505594.2023.2180938</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname>
<given-names>ZX</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>ZG</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Glycine, serine and threonine metabolism confounds efficacy of complement-mediated killing</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):3325. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-11129-5</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonapace</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Bosso</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Friedrich</surname>
<given-names>LV</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Comparison of methods of interpretation of checkerboard synergy testing</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2002</year>;<volume>44</volume>(<issue>4</issue>):<fpage>363</fpage>&#x02013;<lpage>366</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0732-8893(02)00473-X</pub-id><pub-id pub-id-type="pmid">12543542</pub-id>
</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noel</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Keevil</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Wilks</surname>
<given-names>SA.</given-names></string-name></person-group>
<article-title>Synergism versus additivity: defining the interactions between common disinfectants</article-title>. <source>Mbio</source>. <year>2021</year>;<volume>12</volume>(<issue>5</issue>):<fpage>e0228121</fpage>. doi:<pub-id pub-id-type="doi">10.1128/mBio.02281-21</pub-id><pub-id pub-id-type="pmid">34544274</pub-id>
</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peng</surname>
<given-names>LT</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>SQ</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>WX</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Alpha-ketoglutarate downregulates thiosulfate metabolism to enhance antibiotic killing</article-title>. <source>Int J Antimicrob Agents</source>. <year>2024;</year><volume>64</volume>(<issue>2</issue>):<fpage>107214</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2024.107214</pub-id><pub-id pub-id-type="pmid">38795933</pub-id>
</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>XH</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Functional proteomics analysis of norfloxacin-resistant <italic toggle="yes">Edwardsiella tarda</italic></article-title>. <source>J Proteome Res</source>. <year>2023</year>;<volume>22</volume>(<issue>11</issue>):<fpage>3489</fpage>&#x02013;<lpage>3498</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jproteome.3c00365</pub-id><pub-id pub-id-type="pmid">37856871</pub-id>
</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peng</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Su</surname>
<given-names>YB</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria</article-title>. <source>Cell Metab</source>. <year>2015</year>;<volume>21</volume>(<issue>2</issue>):<fpage>249</fpage>&#x02013;<lpage>262</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2015.01.008</pub-id><pub-id pub-id-type="pmid">25651179</pub-id>
</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keren</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Kaldalu</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Spoering</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Persister cells and tolerance to antimicrobials</article-title>. <source>FEMS Microbiol Lett</source>. <year>2004</year>;<volume>230</volume>(<issue>1</issue>):<fpage>13</fpage>&#x02013;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0378-1097(03)00856-5</pub-id><pub-id pub-id-type="pmid">14734160</pub-id>
</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>ZJ</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>YY</given-names></string-name>, <string-name><surname>Bai</surname>
<given-names>LY</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A new therapeutic strategy for infectious diseases against intracellular multidrug-resistant bacteria</article-title>. <source>J Control Release</source>. <year>2024</year>;<volume>375</volume>:<fpage>467</fpage>&#x02013;<lpage>477</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jconrel.2024.09.028</pub-id><pub-id pub-id-type="pmid">39293527</pub-id>
</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Yue</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Microsatellite analysis in two populations of Kunming mice</article-title>. <source>Lab Anim</source>. <year>2009</year>;<volume>43</volume>(<issue>1</issue>):<fpage>34</fpage>&#x02013;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1258/la.2008.008098</pub-id><pub-id pub-id-type="pmid">19141464</pub-id>
</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Su</surname>
<given-names>YB</given-names></string-name>, <string-name><surname>Ye</surname>
<given-names>JZ</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Ampicillin-controlled glucose metabolism manipulates the transition from tolerance to resistance in bacteria</article-title>. <source>Sci Adv</source>. <year>2023</year>;<volume>9</volume>(<issue>10</issue>):eade8582. doi:<pub-id pub-id-type="doi">10.1126/sciadv.ade8582</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Qian</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Addressing MRSA infection and antibacterial resistance with peptoid polymers</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>5898</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-26221-y</pub-id><pub-id pub-id-type="pmid">34625571</pub-id>
</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>
<given-names>XL</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>ZG</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>TC</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Glutamine promotes antibiotic uptake to kill multidrug-resistant uropathogenic bacteria</article-title>. <source>Sci Transl Med</source>. <year>2021</year>;<volume>13</volume>(<issue>625</issue>):<fpage>eabj0716</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.abj0716</pub-id><pub-id pub-id-type="pmid">34936385</pub-id>
</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kou</surname>
<given-names>TS</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>XW</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Exogenous glycine promotes oxidation of glutathione and restores sensitivity of bacterial pathogens to serum-induced cell death</article-title>. <source>Redox Biol</source>. <year>2022</year>;<volume>58</volume>:102512. doi:<pub-id pub-id-type="doi">10.1016/j.redox.2022.102512</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Combining with domiphen bromide restores colistin efficacy against colistin-resistant gram-negative bacteria <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>Int J Antimicrob Agents</source>. <year>2024</year>;<volume>63</volume>(<issue>2</issue>):<fpage>107066</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2023.107066</pub-id><pub-id pub-id-type="pmid">38135012</pub-id>
</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Tong</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Bacterial proton motive force as an unprecedented target to control antimicrobial resistance</article-title>. <source>Med Res Rev</source>. <year>2023</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1068</fpage>&#x02013;<lpage>1090</lpage>. doi:<pub-id pub-id-type="doi">10.1002/med.21946</pub-id><pub-id pub-id-type="pmid">36896761</pub-id>
</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ducasse-Cabanot</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cohen-Gonsaud</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marrakchi</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title><italic toggle="yes">In vitro</italic> inhibition of the <italic toggle="yes">Mycobacterium tuberculosis</italic> beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2004</year>;<volume>48</volume>(<issue>1</issue>):<fpage>242</fpage>&#x02013;<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.48.1.242-249.2004</pub-id><pub-id pub-id-type="pmid">14693546</pub-id>
</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lei</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Tu</surname>
<given-names>SC.</given-names></string-name></person-group>
<article-title>Action mechanism of antitubercular isoniazid. Activation by <italic toggle="yes">Mycobacterium tuberculosis</italic> KatG, isolation, and characterization of inha inhibitor</article-title>. <source>J Biol Chem</source>. <year>2000</year>;<volume>275</volume>(<issue>4</issue>):<fpage>2520</fpage>&#x02013;<lpage>2526</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.275.4.2520</pub-id><pub-id pub-id-type="pmid">10644708</pub-id>
</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turner</surname>
<given-names>TH</given-names></string-name>, <string-name><surname>Alzubi</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Harrell</surname>
<given-names>JC.</given-names></string-name></person-group>
<article-title>Identification of synergistic drug combinations using breast cancer patient-derived xenografts</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1493</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-58438-0</pub-id><pub-id pub-id-type="pmid">32001757</pub-id>
</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stein</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Craig</surname>
<given-names>WA.</given-names></string-name></person-group>
<article-title>Tigecycline: a critical analysis</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>43</volume>(<issue>4</issue>):<fpage>518</fpage>&#x02013;<lpage>524</lpage>. doi:<pub-id pub-id-type="doi">10.1086/505494</pub-id><pub-id pub-id-type="pmid">16838243</pub-id>
</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nemeth</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Oesch</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kuster</surname>
<given-names>SP.</given-names></string-name></person-group>
<article-title>Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis</article-title>. <source>J Antimicrob Chemother</source>. <year>2015</year>;<volume>70</volume>(<issue>2</issue>):<fpage>382</fpage>&#x02013;<lpage>395</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dku379</pub-id><pub-id pub-id-type="pmid">25266070</pub-id>
</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Phe</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Dossot</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Guilloteau</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Nucleic acid fluorochromes and flow cytometry prove useful in assessing the effect of chlorination on drinking water bacteria</article-title>. <source>Water Res</source>. <year>2005</year>;<volume>39</volume>(<issue>15</issue>):<fpage>3618</fpage>&#x02013;<lpage>3628</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.watres.2005.06.002</pub-id><pub-id pub-id-type="pmid">16081129</pub-id>
</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Qiu</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Effects of polyethylene microplastics on cell membranes: a combined study of experiments and molecular dynamics simulations</article-title>. <source>J Hazard Mater</source>. <year>2022</year>;<volume>429</volume>:<fpage>128323</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhazmat.2022.128323</pub-id><pub-id pub-id-type="pmid">35086040</pub-id>
</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Su</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Selectivity for and destruction of <italic toggle="yes">Salmonella typhimurium</italic> via a membrane damage mechanism of a cell-penetrating peptide ppTG20 analogue</article-title>. <source>Int J Antimicrob Agents</source>. <year>2012</year>;<volume>40</volume>(<issue>4</issue>):<fpage>337</fpage>&#x02013;<lpage>343</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.05.026</pub-id><pub-id pub-id-type="pmid">22819152</pub-id>
</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krulwich</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Sachs</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Padan</surname>
<given-names>E.</given-names></string-name></person-group>
<article-title>Molecular aspects of bacterial pH sensing and homeostasis</article-title>. <source>Nat Rev Microbiol</source>. <year>2011</year>;<volume>9</volume>(<issue>5</issue>):<fpage>330</fpage>&#x02013;<lpage>343</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro2549</pub-id><pub-id pub-id-type="pmid">21464825</pub-id>
</mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamaguchi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ohmori</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kaneko-Ohdera</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Delta pH-dependent accumulation of tetracycline in <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>1991</year>;<volume>35</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02013;<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.35.1.53</pub-id><pub-id pub-id-type="pmid">2014981</pub-id>
</mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Plant natural flavonoids against multidrug resistant pathogens</article-title>. <source>Adv Sci (Weinh)</source>. <year>2021</year>;<volume>8</volume>(<issue>15</issue>):<fpage>e2100749</fpage>. doi:<pub-id pub-id-type="doi">10.1002/advs.202100749</pub-id><pub-id pub-id-type="pmid">34041861</pub-id>
</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname>
<given-names>KY</given-names></string-name>, <string-name><surname>Fokkens</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Reggiori</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Parkinson&#x02019;s disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy</article-title>. <source>Transl Neurodegener</source>. <year>2021</year>;<volume>10</volume>(<issue>1</issue>):<fpage>19</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40035-021-00243-4</pub-id><pub-id pub-id-type="pmid">34127073</pub-id>
</mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kwon</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sesaki</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) suppresses STING-mediated DNA sensing pathway through inducing mitochondrial fission</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2017</year>;<volume>493</volume>(<issue>1</issue>):<fpage>737</fpage>&#x02013;<lpage>743</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2017.08.121</pub-id><pub-id pub-id-type="pmid">28859978</pub-id>
</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Tigecycline resistance-associated mutations in the MepA efflux pump in <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>Microbiol Spectr</source>. <year>2023</year>;<volume>11</volume>(<issue>4</issue>):<fpage>e0063423</fpage>. doi:<pub-id pub-id-type="doi">10.1128/spectrum.00634-23</pub-id><pub-id pub-id-type="pmid">37432114</pub-id>
</mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>YM</given-names></string-name>, <string-name><surname>Rock</surname>
<given-names>CO.</given-names></string-name></person-group>
<article-title>Membrane lipid homeostasis in bacteria</article-title>. <source>Nat Rev Microbiol</source>. <year>2008</year>;<volume>6</volume>(<issue>3</issue>):<fpage>222</fpage>&#x02013;<lpage>233</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro1839</pub-id><pub-id pub-id-type="pmid">18264115</pub-id>
</mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baker</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Payne</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Rappuoli</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Technologies to address antimicrobial resistance</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2018</year>;<volume>115</volume>(<issue>51</issue>):<fpage>12887</fpage>&#x02013;<lpage>12895</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1717160115</pub-id><pub-id pub-id-type="pmid">30559181</pub-id>
</mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tyers</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wright</surname>
<given-names>GD.</given-names></string-name></person-group>
<article-title>Drug combinations: a strategy to extend the life of antibiotics in the 21st century</article-title>. <source>Nat Rev Microbiol</source>. <year>2019</year>;<volume>17</volume>(<issue>3</issue>):<fpage>141</fpage>&#x02013;<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41579-018-0141-x</pub-id><pub-id pub-id-type="pmid">30683887</pub-id>
</mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coates</surname>
<given-names>ARM</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Holt</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction</article-title>. <source>Expert Rev Anti Infect Ther</source>. <year>2020</year>;<volume>18</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14787210.2020.1705155</pub-id><pub-id pub-id-type="pmid">31847614</pub-id>
</mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Torres</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Paul</surname>
<given-names>LV</given-names></string-name>, <string-name><surname>Rodwell</surname>
<given-names>TC</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Novel katG mutations causing isoniazid resistance in clinical <italic toggle="yes">M. tuberculosis</italic> isolates</article-title>. <source>Emerg Microbes Infect</source>. <year>2015</year>;<volume>4</volume>(<issue>7</issue>):<fpage>e42</fpage>. doi:<pub-id pub-id-type="doi">10.1038/emi.2015.42</pub-id><pub-id pub-id-type="pmid">26251830</pub-id>
</mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yaghoubi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zekiy</surname>
<given-names>AO</given-names></string-name>, <string-name><surname>Krutova</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>2022</year>;<volume>41</volume>(<issue>7</issue>):<fpage>1003</fpage>&#x02013;<lpage>1022</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10096-020-04121-1</pub-id><pub-id pub-id-type="pmid">33403565</pub-id>
</mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Veeraraghavan</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Poojary</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shankar</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title><italic toggle="yes">In-vitro</italic> activity of tigecycline and comparator agents against common pathogens: Indian experience</article-title>. <source>J Infect Dev Ctries</source>. <year>2019</year>;<volume>13</volume>(<issue>3</issue>):<fpage>245</fpage>&#x02013;<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.3855/jidc.10376</pub-id><pub-id pub-id-type="pmid">32040455</pub-id>
</mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nair</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Jacob</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>A simple practice guide for dose conversion between animals and human</article-title>. <source>J Basic Clin Pharm</source>. <year>2016</year>;<volume>7</volume>(<issue>2</issue>):<fpage>27</fpage>&#x02013;<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0976-0105.177703</pub-id><pub-id pub-id-type="pmid">27057123</pub-id>
</mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ranjalkar</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mathew</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Verghese</surname>
<given-names>VP</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India</article-title>. <source>Int J Antimicrob Agents</source>. <year>2018</year>;<volume>51</volume>(<issue>5</issue>):<fpage>663</fpage>&#x02013;<lpage>669</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.12.004</pub-id><pub-id pub-id-type="pmid">29241821</pub-id>
</mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cojutti</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Giangreco</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Isola</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Limited sampling strategies for determining the area under the plasma concentration&#x02013;time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis</article-title>. <source>Int J Antimicrob Agents</source>. <year>2017</year>;<volume>50</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.01.036</pub-id><pub-id pub-id-type="pmid">28495479</pub-id>
</mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Babu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Khan</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Srivastava</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Isoniazid induces a monocytic-like phenotype in HL-60&#x0202f;cells</article-title>. <source>Arch Biochem Biophys</source>. <year>2019</year>;<volume>664</volume>:<fpage>15</fpage>&#x02013;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.abb.2019.01.004</pub-id><pub-id pub-id-type="pmid">30682330</pub-id>
</mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamashiro</surname>
<given-names>LH</given-names></string-name>, <string-name><surname>Eto</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Soncini</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Isoniazid-induced control of <italic toggle="yes">Mycobacterium tuberculosis</italic> by primary human cells requires interleukin-1 receptor and tumor necrosis factor</article-title>. <source>Eur J Immunol</source>. <year>2016</year>;<volume>46</volume>(<issue>8</issue>):<fpage>1936</fpage>&#x02013;<lpage>1947</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.201646349</pub-id><pub-id pub-id-type="pmid">27230303</pub-id>
</mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>DM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action</article-title>. <source>Cell Host Microbe</source>. <year>2012</year>;<volume>11</volume>(<issue>5</issue>):<fpage>457</fpage>&#x02013;<lpage>468</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2012.03.008</pub-id><pub-id pub-id-type="pmid">22607799</pub-id>
</mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Su</surname>
<given-names>YB</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Fructose restores susceptibility of multidrug-resistant <italic toggle="yes">Edwardsiella tarda</italic> to kanamycin</article-title>. <source>J Proteome Res</source>. <year>2015</year>;<volume>14</volume>(<issue>3</issue>):<fpage>1612</fpage>&#x02013;<lpage>1620</lpage>. doi:<pub-id pub-id-type="doi">10.1021/pr501285f</pub-id><pub-id pub-id-type="pmid">25675328</pub-id>
</mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sabnis</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hagart</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Klockner</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane</article-title>. <source>Elife</source>. <year>2021</year>;<volume>10</volume>:e65836. doi:<pub-id pub-id-type="doi">10.7554/eLife.65836</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Su</surname>
<given-names>YB</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Pyruvate cycle increases aminoglycoside efficacy and provides respiratory energy in bacteria</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2018</year>;<volume>115</volume>(<issue>7</issue>):<fpage>E1578</fpage>&#x02013;<lpage>E1E87</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1714645115</pub-id><pub-id pub-id-type="pmid">29382755</pub-id>
</mixed-citation></ref></ref-list></back></article>